HealthWarehouse.com FY2025 net sales rose 46% to USD 49 million

Reuters03-20 20:03
HealthWarehouse.com FY2025 net sales rose 46% to USD 49 million
  • HealthWarehouse published a full-year earnings release for the year ended Dec. 31, 2025, reporting net sales of USD 49 million, up 46% on 87% growth in partner services prescription revenues that was partly offset by a decline in direct-to-consumer sales.
  • Gross profit was USD 17.1 million, while gross margin fell 7 percentage points to 35% due to lower margins in the B2B prescription business for branded and compounded drugs.
  • Selling, general and administrative expenses were USD 16.7 million, up 17.7% as higher order volume drove increases including shipping, salaries and software and engineering costs.
  • Net income was USD 265,000 and Adjusted EBITDA was USD 1.6 million, while management cited positive cash flow of USD 1.6 million as reflected by Adjusted EBITDA.
  • Joseph Peters said sales of compounded versions of certain GLP-1 prescription medications were declining, and the company said its authority to dispense high-dollar compounded GLP-1 medications ended in 2025 and is expected to significantly affect 2026 sales while it expects positive cash from operations in 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HealthWarehouse.com Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260320532120) on March 20, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment